©1995 by The American Society for Biochemistry and Molecular Biology, Inc.
Specificity in Recognition of Amyloid- Peptide by the Serpin-Enzyme Complex Receptor in Hepatoma Cells and Neuronal Cells (*)

(Received for publication, August 15, 1995)

Kimberly Boland Karen Manias David H. Perlmutter (§)

From the Department of Pediatrics, Cell Biology, and Physiology, Washington University School of Medicine, Division of Gastroenterology and Nutrition, St. Louis Children's Hospital, St. Louis, Missouri 63110

ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
FOOTNOTES
ACKNOWLEDGEMENTS
REFERENCES

ABSTRACT

The serpin-enzyme complex (SEC) receptor was originally identified using a synthetic peptide (peptide 105Y) based on the sequence of a candidate receptor-binding domain of alpha1-antitrypsin (1-AT) and was subsequently shown to be a receptor on the surface of hepatocytes, monocytes, and neutrophils for recognition of alpha1-AT-elastase and several other serpin-enzyme complexes (Perlmutter, D. H., Glover, G. I., Rivetna, M., Schasteen, C. S., and Fallon, R. J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 3753-3757). Studies of the minimal requirements for binding to SEC receptor (SEC-R) showed that a pentapeptide FVFLM within the carboxyl-terminal tail of alpha1-AT was sufficient for binding to SEC-R and interacted with SEC-R in a sequence-specific manner (Joslin, G., Krause, J. E., Hershey, A. D., Adams, S. P., Fallon, R. J., and Perlmutter, D. H.(1991) J. Biol. Chem. 266, 21897-21902). Sequence motifs bearing homology with this pentapeptide domain were found in the amyloid-beta peptide, and amyloid-beta peptide 1-42 was shown to compete for binding to SEC-R on hepatoma cells (Joslin, G., Fallon, R. J., Bullock, J., Adams, S. P., and Perlmutter, D. H.(1991) J. Biol. Chem. 266, 11281-11288). In this study we examined the sequence specificity by which amyloid-beta peptide competes for binding to SEC-R and examined the possibility that SEC-R is expressed in cells of neuronal origin. The results show that amyloid-beta-(25-35) and amyloid-beta-(31-35) compete for binding to SEC-R as effectively as amyloid-beta-(1-39), amyloid-beta-(1-40), and amyloid-beta-(1-42). Amyloid-beta-(1-16) does not compete for binding to SEC-R. There is cross-competition for binding to the same site by I-peptide 105Y and amyloid-beta-(25-35) as well as by I-Y amyloid-beta-(25-35) and peptide 105Y. By deletions and substitutions within amyloid-beta-(25-35) and generation of chimeric amyloid-beta-alpha1-AT peptides, amyloid-beta-(31-35) is shown to be critical for binding to the SEC receptor. However, the upstream region, amyloid-beta-(25-30), also contributes to recognition by SEC-R. The SEC-R is present on the surface of a neuronal cell line PC12 as well as that of murine cortical neurons in primary culture, and the specificity of neuronal SEC-R for amyloid-beta peptide is identical to that on hepatoma cells. Finally, SEC-R mediates internalization and degradation of amyloid beta-peptide in PC12 cells. These results provide evidence that SEC-R plays a role in metabolism of amyloid-beta peptide in the nervous system.


INTRODUCTION

The serpin-enzyme complex receptor (SEC-R) (^1)is a cell surface protein of hepatoma cells, mononuclear phagocytes, and neutrophils that has a ligand binding subunit of 70-78 kDa (reviewed in (1) ). It was originally identified as the receptor responsible for feed-forward regulation of alpha1-AT synthesis by complexes of neutrophil elastase and alpha1-AT. A synthetic peptide, peptide 105Y (SIPPEVKFNKPFVYLI), based on the sequence of a candidate receptor-binding domain in the carboxyl-terminal tail of alpha1-AT itself, was shown to mediate increases in synthesis of alpha1-AT in human monocytes and human hepatoma HepG2 cells(2) . Radioiodinated peptide 105Y bound to HepG2 cells with specific, saturable, and reversible characteristics. Scatchard analysis predicted a k of 40 nM and 450,000 plasma membrane receptors/cell(2) . Binding of I-peptide 105Y to HepG2 cells was blocked by unlabeled elastase-alpha1-AT, cathepsin G-alpha1-antichymotrypsin, thrombin-antithrombin III, thrombin-heparin cofactor II, and, to a lesser extent, C1s-C1 inhibitor and tissue plasminogen activator-plasminogen activator inhibitor I complexes but not by the corresponding native proteins(2, 3) . Binding of radioiodinated elastase-alpha1-AT, cathepsin G-alpha1-antichymotrypsin, thrombin-antithrombin III, thrombin-thrombin-heparin cofactor II, and tissue plasminogen activator-plasminogen activator inhibitor I to HepG2 cells was also partially, but specifically, blocked by peptide 105Y(2, 3) . Other studies have shown that SEC-R mediates endocytosis and intracellular catabolism of elastase-alpha1-AT complexes in HepG2 cells (4) and mediates directed migration of neutrophils toward alpha1-AT-elastase complexes(5) .

In studies designed to determine the minimal requirements for binding to SEC-R, a series of smaller peptides based on the sequence of peptide 105Y were synthesized(6) . The studies showed that the carboxyl-terminal pentapeptide FVYLI and its counterpart in the native alpha1-AT sequence, FVFLM, were sufficient for binding to SEC-R and that interaction between these pentapeptides and SEC-R was sequence-specific. A search for homologous sequences in other eukaryotic proteins showed similarities in the carboxyl-terminal regions of substance P, several other tachykinins, bombesin, and amyloid-beta peptide(6) . In fact, the homologous region of amyloid-beta peptide, amyloid-beta-(25-35), is toxic to neurons(7) . It constitutes the minimal peptide sequence for the neurotoxic effect of amyloid-beta-(1-42) (7) and, therefore, has been considered a possible common final pathway for the neuronal degeneration in Alzheimer's disease. Studies in HepG2 cells have subsequently shown that amyloid-beta peptide competes for binding of radioiodinated peptide 105Y and radioiodinated elastase-alpha1-AT complexes to SEC-R(8) . Moreover, binding of amyloid-beta peptide to SEC-R in neutrophils results in chemotactic activity and confers homologous desensitization to the chemotactic activity of peptide 105Y(5) .

In this study we examined the sequence specificity for binding of amyloid-beta peptide to SEC-R of the model hepatoma cell line HepG2 and examined the possibility that SEC-R is expressed on the surface of neurons in primary culture and in a transformed neuronal cell line.


EXPERIMENTAL PROCEDURES

Materials

Amyloid-beta-(1-16), amyloid-beta-(1-39), amyloid-beta-(1-40), and amyloid-beta-(1-42) were purchased from Bachem California. Peptide 105Y, amyloid-beta peptide-(25-35), amyloid-beta peptide-(31-35), Yambeta-(25-35), and all other deleted, substituted, swapped, and chimeric peptides were synthesized by the solid phase method, purified, and subjected to amino acid composition and sequence analysis as described previously(6) . The sequence of peptide 105Y is based on the sequence of alpha1-AT 359-374 except for the substitution of tyrosine for phenylalanine 372 to permit radioiodination and isoleucine for methionine 374, a substitution that had been introduced in the original series of peptides for ease of synthesis(2) . Studies done since that time have shown that there is no significant difference in binding to SEC-R for peptides in which isoleucine or methionine occupies residue 374(6) .

Since many of these peptides, particularly the amyloid-beta peptides, are not soluble in H(2)0, all were prepared in Me(2)SO to ensure that they were completely dissolved and could be compared with each other.

Cell Culture

Maintenance of HepG2 cells has been previously described(4) . For binding and internalization studies, HepG2 cells were subcultured into 24-well plates and used when confluent. PC12 cells were kindly provided by Drs. Eugene Johnson and Karen O'Malley (St. Louis, MO). Primary cultures of mouse cortical neurons (9) were provided by Howard Ying and Dennis Choi (St. Louis, MO).

Determination of Cell Surface Receptor Binding

Peptide 105Y, Yambeta-(25-35), and amyloid-beta-(1-40) were radioiodinated by the chloramine T method. I-peptide 105Y and I-amyloid-beta-(1-40) were purified on Biogel P2 and I-Yambeta-(25-35) (YGSNKGAIIGLM) was purified on Sephadex G10. Specific radioactivity for I-peptide 105Y and I-Yambeta-(25-35) varied from 25,000 to 35,000 cpm/ng and I-amyloid-beta-(1-40) from 6,000 to 10,000 cpm/ng. For binding studies in HepG2 cells, separate monolayers in 24-well plates were dunked in phosphate-buffered saline and incubated for 2 h at 4 °C in I-labeled ligand in the absence or presence of competitor and diluted in binding medium (Dulbecco's modified Eagle's medium containing 10 mM Hepes, 0.1 mg/ml cytochrome c, 0.01% Tween 80, 1 mg/ml bovine serum albumin). The cells were then rinsed in phosphate-buffered saline, and cell-associated radioactivity was determined in 1 N NaOH homogenates. For binding studies in PC12 cells and murine cortical neurons, cells were detached from tissue culture flasks, washed with phosphate-buffered saline supplemented with 3 mM EDTA, and then, in suspension, incubated for 2 h at 4 °C with a I-labeled ligand with and without competitors diluted in suspension binding medium (phosphate-buffered saline, 3 mM EDTA, 1 mg/ml bovine serum albumin, and 0.01% Tween 80). At the end of this time interval, cells were lysed in 1 N NaOH and cell-associated radioactivity was determined. Specific binding was defined as the difference between total binding in the absence of unlabeled competitor and nonspecific binding in the presence of unlabeled competitor. Nonspecific binding varied from 8 to 30% depending on individual radioligand and individual radioligand preparations. Methods for Scatchard analysis have been previously described(2) .

Determination of Cellular Uptake, Internalization, and Degradation

HepG2 cells were washed with PBS and then incubated at 37 °C for time intervals up to 6 h with I-ligand diluted in uptake medium (Dulbecco's modified Eagle's medium containing 10 mM Hepes, 0.1 mg/ml cytochrome c, 1 mg/ml bovine serum albumin). At specific time intervals, cell culture fluid was harvested, and cells were homogenized in 1 N NaOH. Homogenates were then subjected to scintillation counting to determine ``total uptake.'' Specific uptake was defined as the difference between total and nonspecific uptake. In other experiments, cell surface and internal fractions of cell-associated radioactivity were determined by incubating cell monolayers or cell pellets for an additional 1 h at 4 °C in PBS with proteinase K (0.5 mg/ml). The effect of proteinase K was terminated by the addition of 1 mM phenylmethylsulfonyl fluoride. Cells were then detached by gentle agitation and pelleted by centrifugation. Radioactivity in these cell pellets was defined as proteinase K-resistant or internal fraction, and that in the supernatants was defined as proteinase K-sensitive or cell surface fraction. Radioactivity in the cell culture fluid was determined before and after precipitation with 20% trichloroacetic acid, 4% phosphotungstic acid. This procedure precipitated greater than 97% of the radioactivity present at time 0 in medium containing I-amyloid-beta-(1-40).

In order to determine the distribution of I-amyloid-beta peptide-(1-40) during a single cycle of endocytosis we used a previously described protocol(10, 11) . HepG2 cells or PC12 cells were incubated for 2 h at 4 °C with I-amyloid-beta-(1-40) in saturating concentrations (100 nM). Cell monolayers were rinsed and then incubated at 37 °C for several different time intervals in uptake medium alone. Cell culture fluid was harvested, and cell monolayers were rinsed and incubated for an additional 60 min in PBS alone or PBS containing proteinase K as described above to determine proteinase K-resistant uptake (internal fraction) and proteinase K-sensitive uptake (surface-bound fraction). Cell culture fluid was counted before (total extracellular ligand) and after acid precipitation (acid-soluble extracellular ligand).


RESULTS

Specific Region within Amyloid-beta Peptide That Is Recognized by the SEC Receptor

In previous studies we showed that amyloid-beta-(1-42) competed for binding of I-peptide 105Y to HepG2 cells(8) . In order to determine if this competition was truly attributable to the amyloid-beta-(25-35) region, and particularly to the amyloid-beta-(31-35) region, we examined the capacity for several amyloid-beta peptides to compete for binding of I-peptide 105Y to HepG2 cells (Fig. 1). There was concentration-dependent inhibition of binding by amyloid-beta-(25-35), comparable with that of unlabeled peptide 105Y (Fig. 1a). Amyloid-beta-(31-35) also competed for binding of I-peptide 105Y, but to a slightly lesser extent. Amyloid-beta-(1-16) did not compete at all. There were no significant differences in the capacity for synthetic peptides corresponding to naturally occurring amyloid-beta peptide-(1-40) and amyloid-beta-peptide-(1-42), when completely soluble in Me(2)SO, to compete for binding, but again amyloid-beta-(1-16) did not compete for binding at all (Fig. 1b). Amyloid-beta peptide-(1-39) was also as effective as amyloid-beta-(1-40) and amyloid-beta-(1-42) as a competitor for binding of I-peptide 105Y (data not shown). These data indicated that amyloid-beta-(25-35), and particularly amyloid-beta-(31-35), was responsible for recognition by SEC-R and that this region could be presented to the SEC-R by several different naturally occurring amyloid-beta peptides in their soluble form.


Figure 1: Competition for binding of I-peptide 105Y to HepG2 cells by amyloid-beta peptides. Cells were incubated for 2 h at 4 °C with binding buffer, I-peptide 105Y in subsaturating concentrations (50 nM) in the absence of competitors (designated 100% total binding) or in the presence of competitors in several different concentrations as shown on the horizontal axis. At the end of this time interval, cells were lysed and cell lysates were subjected to counting. Results are reported as mean ± 1 standard deviation for at least three separate determinations. Sequences of the peptide are compared with the alpha1-AT sequence at the top. a, peptides 105Y, amyloid-beta-(25-35), amyloid-beta-(31-35), and amyloid-beta-(1-16). b, peptides amyloid-beta-(1-40), amyloid-beta-(1-42), and amyloid-beta-(1-16).



In order to provide further evidence that amyloid-beta-(25-35) was involved in SEC-R binding and to do cross-competition studies, we first examined the direct binding of I-Yambeta-(25-35) (YGSNKGAIIGLM) to HepG2 cells (Fig. 2a). There was specific and saturable binding. Scatchard analysis predicted a k(d) of 32.1 nM and 430,000 plasma membrane receptors/cell. This is very similar to the characteristics by which I-peptide 105Y binds to HepG2 cells(2) . In separate experiments using I-amyloid-beta-(1-40) and unlabeled peptide 105Y in HepG2 cells, binding characteristics were also similar to those of I-peptide 105Y (k(d) of 35.3 nM and 2.3 times 10^5 plasma membrane receptors/cell). Finally, in cross-competition studies, there was no significant difference between unlabeled Yambeta-(25-35) and peptide 105Y in competition for binding of I-Yambeta-(25-35) to HepG2 cells (Fig. 2b).


Figure 2: a, direct binding of I-Yambeta-(25-35) to HepG2 cells. Cells were incubated for 2 h at 4 °C with binding buffer, I-Yambeta-(25-35) in several different concentrations as shown on the horizontal axis in the absence of any competitor (Total) or in the presence of unlabeled Yambeta-(25-35) in 200-fold molar excess (Nonspecific). Cells were then washed extensively and lysed, and cell lysates were subjected to counting. Results are reported as mean ± 1 standard deviation for at least three separate determinations. Scatchard plot analysis is shown in the inset. b, cross-competition for binding of I-Yam-beta-(25-35) by peptide 105Y. HepG2 cells were incubated for 2 h at 4 °C with binding buffer, I-Yambeta-(25-35) in subsaturating concentrations (50 nM) in the absence of competitors (designated 100% total binding) or in the presence of unlabeled peptide 105Y or unlabeled Yambeta-(25-35) in the concentrations indicated on the horizontal axis. Results are reported as mean ± 1 standard deviation.



Evidence for Expression of the SEC Receptor in Neuronal Cells

First, we examined the possibility that I-peptide 105Y binds to the neuronal cell line PC12 (Fig. 3a). There was specific and saturable binding with a k(d) of 32.3 nM and 180,000 plasma membrane receptors/cell. The results were almost identical when I-amyloid-beta-(1-40) and unlabeled peptide 105Y were used in PC12 cells (data not shown). Moreover, cross-competition studies showed that unlabeled amyloid-beta-(25-35) and peptide 105Y were similar in efficacy of competition for binding of I peptide 105Y and I-Yambeta-(25-35) to PC12 cells (Fig. 3b). These results indicated that the SEC-R was expressed in at least one neuronal cell line and that it had similar characteristics in rat and human cells. In order to exclude the possibility that it was only present on transformed neuronal cells, we also examined binding of I-peptide 105Y to cortical neurons in primary culture (Fig. 3c). The results indicate that there is specific and saturable binding. The point of half-maximal binding at 30-40 nM is similar to that seen for binding of peptide 105Y to HepG2 cells, neutrophils, and PC12 cells. Taken together, these results indicate that the SEC-R is expressed in neuronal cells.


Figure 3: a, direct binding of I-peptide 105Y to PC12 cells. PC12 cells were incubated for 2 h at 4 °C with PC12 binding buffer, I-peptide 105Y in several different concentrations as shown on the horizontal axis in the absence of any competitor (Total) or in the presence of unlabeled peptide 105Y in 200-fold molar excess (nonspecific). The difference represents specific binding. Scatchard plot analysis is shown in the inset. b, cross-competition for binding of I-peptide 105Y (left panel) and binding of I-Yambeta-(25-35) (right panel) to PC12 cells by unlabeled peptide 105Y and unlabeled amyloid-beta-(25-35), exactly as described in the legend for Fig. 2b. c, direct binding of I-peptide 105Y to cortical neurons in primary culture. Exactly as described in the legends for Fig. 3a except with murine cortical neurons.



Sequence Specificity by Which Amyloid-beta-(25-35) Binds to the SEC Receptor

On the basis of previous experience with the sequence specificity by which peptide 105Y and alpha1-AT interact with SEC-R (2, 3, 4, 5, 6, 8) , we generated synthetic peptides based on the sequence of amyloid-beta-(25-35) but engineered with selected substitutions and deletions. First, these substituted and deleted peptides were examined as competitors for binding of I-peptide 105Y to HepG2 cells (Fig. 4a). The results show that substitution of alanine for the carboxyl-terminal methionine (peptide ambeta-(25-34A)) and deletion of carboxyl-terminal leucine and methionine residues (peptide ambeta-(25-33)) markedly reduces competitive binding efficacy, but substitution of alanine for the amino-terminal residue (peptide ambeta-(25A-35)) or deletion of two amino-terminal residues (peptide ambeta-(27-35)) do not reduce competitive binding efficacy. Deletion of the carboxyl-terminal glycine-leucine-methionine sequence (peptide Yambeta-(22-32)) completely abrogates binding even if the overall length of the peptide remains similar by adding residues from the amyloid-beta peptide sequence at the amino terminus. Again, the carboxyl-terminal pentapeptide amyloid-beta-(31-35) is almost as effective as amyloid-beta-(25-35) as a competitor. These data show that the carboxyl-terminal residues of amyloid-beta-(25-35) play an important role in binding to SEC-R. The results were similar when the same peptides were used as competitors for binding ofI-Yambeta-(25-35) (Fig. 4b), except that peptides with carboxyl-terminal substitutions and deletions were slightly more effective as competitors and the carboxyl-terminal pentapeptide was slightly less effective as a competitor. This suggests that the amino-terminal region of amyloid-beta-(25-35) may play a more important role than the amino-terminal region of peptide 105Y in recognition by SEC-R.


Figure 4: Competition for binding of I-peptide 105Y (a) and I-Yambeta-(25-35) (b) in HepG2 cells by deleted and substituted amyloid-beta peptides. Exactly as described in the legend to Fig. 1.



Next, we examined several chimeric amyloid-beta/alpha1-AT peptides as competitors for binding of I-peptide 105Y (Fig. 5a) andI-Yambeta-(25-35) (Fig. 5b) to HepG2 cells. The amyloid-beta/alpha1-AT chimeric had the amino-terminal domain of amyloid-beta and carboxyl-terminal domain of alpha1-AT, and the alpha1-AT/amyloid-beta chimera had the reverse. There were no significant differences in competitive binding efficacy of these chimeric peptides as compared with each other and as compared with the original peptides 105Y and amyloid-beta-(25-35). In this design, then, one could not discern a greater role for the amino-terminal domain of amyloid-beta-(25-35) than the corresponding domain of peptide 105Y in recognition by SEC-R.


Figure 5: Competition for binding of I-peptide 105Y (a) and I-Yambeta-(25-35) (b) in HepG2 cells by chimeric amyloid-beta/alpha1-AT peptides. Exactly as described in the legend to Fig. 1.



Comparison of the amino-terminal region of amyloid-beta-(25-35) with the corresponding region of peptide 105Y reveals a conserved asparagine-lysine sequence. In peptide 105Y this is separated from the carboxyl-terminal pentapeptide by a single proline residue, whereas the sequence in amyloid-beta-(25-35) is separated from the carboxyl-terminal pentapeptide by two residues, glycine-arginine. We examined the significance of this difference by generating synthetic peptides in which the intervening proline and glycine-arginine residues were swapped-i.e. GSNK-P-IIGLM; VKFNK-GA-FVFLM (Fig. 6). The results show no significant differences from peptide 105Y or amyloid-beta-(25-35) as competitors for binding of I-peptide 105Y (Fig. 6a) or of I-Yambeta-(25-35) (Fig. 6b). In contrast, however, substitution of two threonine residues for the two isoleucine residues at amyloid-beta 31-32 (peptide ambeta-(25-35)TT) markedly decreases the efficacy of competition for binding to SEC-R. These data provide further evidence that the carboxyl-terminal pentapeptide is critical for binding to SEC-R but also suggest that relative hydrophobicity is required even at residues 31-32.


Figure 6: Competition for binding of I-peptide 105Y (a) and I-Yambeta-(25-35) (b) in HepG2 cells by swapped amyloid-beta/alpha1-AT peptides. The procedure was exactly as described in the legend to Fig. 1.



Using the same deleted, substituted, chimeric, and swapped peptides, the sequence specificity of recognition of amyloid-beta peptide by SEC-R was similar, if not identical, in PC12 cells and HepG2 cells (data not shown). Taken together, these data show that the carboxyl-terminal residues of amyloid-beta-(25-35) are particularly important in binding to SEC-R in hepatoma and neuronal cells.

Internalization of Amyloid-beta Peptide Mediated by the SEC Receptor

Next, we examined the possibility that SEC-R mediates endocytosis and intracellular catabolism of amyloid-beta peptide. First, we examined internalization of I-amyloid-beta-(1-40) in the absence or presence of excess unlabeled peptide 105Y in HepG2 cells (Fig. 7). There was specific, time-dependent, and saturable internalization with steady state reached by 120 min. Kinetics of internalization of I-Yambeta-(25-35) in HepG2 cells and internalization of I-Yambeta-(25-35) and I-amyloid-beta-(1-40) in PC12 cells were similar (data not shown). We also subjected I-amyloid-beta-(1-40) to single cohort studies in PC12 cells (Fig. 8) to determine the distribution of amyloid-beta peptide during a single cycle of endocytosis. PC12 cells were incubated for 2 h at 4 °C with I-amyloid-beta-(1-40) in saturating concentrations. Cell monolayers were rinsed extensively and then incubated at 37 °C in uptake medium without any labeled ligand to examine the fate of the prebound cohort of labeled ligand. At several different time intervals, cell culture fluid was harvested, and cell monolayers were rinsed extensively again and incubated at 4 °C for an additional 1 h in PBS alone or PBS containing proteinase K to determine total uptake, proteinase K-resistant uptake (internal fraction), and proteinase K-sensitive uptake (surface-bound fraction). Cell culture fluid was subjected to scintillation counting before and after acid precipitation to determine the kinetics of dissociation of prebound ligand and the kinetics of appearance of acid-soluble ligand degradation products, respectively. The results show that once bound to cell surface receptor, labeled amyloid-beta-(1-40) disappears from the cell surface within 5-10 min (proteinase K-sensitive fraction) coincident with its accumulation within the cells (proteinase K-resistant fraction) and dissociation from cell surface into the extracellular fluid (total extracellular ligand). During the next 40 min the intracellular concentration of labeled amyloid-beta-(1-40) decreases coincident with the appearance of ligand degradation products in the extracellular fluid (acid-soluble extracellular ligand).


Figure 7: Internalization of I-amyloid-beta peptide-(1-40) in HepG2 cells. Cells were incubated for several different time intervals (horizontal axis) at 37 °C in uptake medium, I-amyloid-beta peptide at saturating concentrations (100 nM), in the absence of competitor (Total), or in the presence of unlabeled peptide 105Y in 200-fold molar excess (Nonspecific). At the end of each time interval the cells were washed and incubated for 1 h at 4 °C in phosphate-buffered saline supplemented with proteinase K. The effect of proteinase K was terminated by the addition of phenylmethylsulfonyl fluoride (1 mM). Cells were then detached by gentle agitation, pelleted by centrifugation, and washed, and the pellets were lysed for counting. Specific internalization represents the difference between total and nonspecific.




Figure 8: Distribution of I-amyloid-beta peptide-(1-40) in PC12 cells during a single cycle of endocytosis. PC12 cells were incubated for 2 h at 4 °C with I-amyloid-beta-(1-40) in saturating concentrations (100 nM), washed extensively, and then incubated in PC12 medium alone at 37 °C for several different time intervals as indicated on the horizontal axis. At the end of each time interval the extracellular medium was harvested, and the cells were incubated for another 1 h at 4 °C in PBS with proteinase K. Phenylmethylsulfonyl fluoride was added to 1 mM, and the cells were pelleted by centrifugation. The supernatant of this initial centrifugation was counted as the proteinase-K-sensitive cell fraction (cell surface-bound radioactivity). The cell pellet was washed extensively in PBS/1 mM phenylmethylsulfonyl fluoride, and then lysed and counted as the proteinase K-resistant cell fraction (internalized radioactivity). The extracellular medium was counted first (total extracellular ligand-dissociated ligand). This medium was then subjected to trichloroacetic acid-phosphotungstic acid precipitation, and the supernatant was counted as the acid-soluble extracellular ligand (ligand degradation products). The results are representative of three separate experiments.



The data provide evidence that amyloid-beta-(1-40), when soluble and recognized by SEC-R, is internalized and degraded in cells of neuronal origin. Furthermore, the kinetics of endocytosis and degradation are similar to that for another SEC-R ligand, the alpha1-AT-elastase complex (4) .


DISCUSSION

The results of these experiments show that soluble amyloid-beta peptide is recognized by SEC-R on neuronal cells as well as hepatoma cells. The binding characteristics of SEC-R on neuronal cells are very similar to those on hepatoma cells. As predicted by previous sequence comparisons, the SEC-R-binding domain of amyloid-beta peptide lies within amyloid-beta-(25-35). This region is presented to SEC-R to a relatively equivalent extent by amyloid-beta-(1-40), amyloid-beta-(1-42), amyloid-beta-(1-39), and amyloid-beta-(25-35) itself when the peptides are prepared and studied in a soluble state. The fact that soluble amyloid-beta-(1-39), amyloid-beta-(1-40), and amyloid-beta-(1-42) compete for binding as well as amyloid-beta-(25-35) is important because these peptides have been found in vivo under physiological conditions(12, 13, 14, 15, 16) . There is no evidence that amyloid-beta-(25-35), which is much easier and more economical to use experimentally, is found as a free peptide in vivo. SEC-R also mediates endocytosis of amyloid-beta peptide in neuronal and hepatoma cell lines. Single cohort studies show that the internalized amyloid-beta peptide is subjected to intracellular degradation. The kinetics of internalization and catabolism are very similar to that of another SEC-R ligand, the alpha1-AT-elastase complex.

Using synthetic peptides based on the sequences of SEC-R-binding domain of alpha1-AT and amyloid-beta peptide and subjecting them to deletion, substitution, and swapping of domains, we have described several characteristics of the sequence specificity by which amyloid-beta peptide binds to SEC-R. First, the carboxyl-terminal pentapeptide (amyloid-beta-(31-35), IIGLM) plays a particularly important role in binding to SEC-R. Substitution of the carboxyl-terminal methionine with alanine or deletion of two or three carboxyl-terminal residues results in a marked decrease in binding. The pentapeptide alone can effectively compete for binding of I-Yambeta-(25-35) and I-peptide 105Y. Second, the amino-terminal domain of amyloid-beta-(25-35) does not appear to play an important role in SEC-R-binding. Substitution of alanine for the amino-terminal glycine or deletion of the two amino-terminal residues did not affect binding at all. Nevertheless, there was some evidence in the current study which suggested that the amino-terminal domain of amyloid-beta-(25-35) may contribute to its binding to SEC-R. Peptides in which two or three carboxyl-terminal residues of amyloid-beta-(25-35) were deleted (amyloid-beta-(25-33), Yambeta-(22-32)) competed more effectively for binding of I-Yambeta-(25-35) than of I-peptide 105Y. Amyloid-beta-(25-33) and Yambeta-(22-32) competed more effectively for binding of I-Yambeta-(25-35) and I-peptide 105Y than did a peptide from the corresponding region of alpha1-AT and of peptide 105Y, called peptide 105B in previous publications(3, 4, 5, 6) . Further evaluation of this issue will require characterization of the structure of the ligand-binding domain of SEC-R.

There is an asparagine-lysine sequence within the amino-terminal domain of amyloid-beta-(25-35) and within the corresponding region of peptide 105Y, but it is separated from the carboxyl-terminal pentapeptide by two amino acids, glycine-alanine, in amyloid-beta-(25-35) as compared with one amino acid, proline, in peptide 105Y. The length or sequence in this region does not appear to affect receptor binding for either ligand. In contrast, substitution of the two isoleucine residues at positions 31 and 32 of amyloid-beta-(25-35) with two threonine residues significantly decreases binding to SEC-R. These data on sequence specificity will be useful in designing receptor agonists and antagonists.

Taken together with our previous studies(5, 8) , the data reported here provide extensive pharmacological evidence that soluble amyloid-beta peptide and peptide 105Y, based on the sequence of alpha1-AT, bind to the same site, called SEC-R, on HepG2 cells, PC12 cells, and neutrophils. First, amyloid-beta-(1-42) competes for cross-linking of an 70-76-kDa radiolabeled polypeptide in HepG2 cells by a photoreactive derivative of peptide 105Y(8) . The cross-linking of this 76-kDa polypeptide is highly specific as shown by positive and negative control competitors and by the absence of any cross-linking in a SEC-R-negative cell line CHO(8) . Second, there is cross-competition for binding to HepG2 cells by I-peptide 105Y and unlabeled amyloid-beta-(1-42) and by I-amyloid-beta-(1-42) and unlabeled peptide 105Y(8) . Third, we show here that the region within amyloid-beta-(1-42) responsible for this cross-competition is amyloid-beta-(25-35) (Fig. 1, a and b) and that there is cross-competition for binding to HepG2 cells (Fig. 2b) and PC12 cells (Fig. 3b) by I-peptide 105Y and unlabeled Yam-beta-(25-35) and by I-Yam-beta-(25-35) and unlabeled peptide 105Y. Fourth, Scatchard plot analysis of binding characteristics of I-Yambeta-(25-35) to HepG2 cells are almost identical to that of I-peptide 105Y (Fig. 2a). Fifth, experiments with several series of peptides based on the sequences of amyloid-beta-(25-35) but modified by deletions, substitutions, or swapping show that these peptides compete to a similar extent for binding to HepG2 cells of I-peptide 105Y and I-Yam-beta-(25-35) ( Fig. 4and Fig. 6). Sixth, an alpha1-AT/ambeta chimeric peptide, composed of the amino-terminal domains of peptide 105Y and the carboxyl-terminal domain of ambeta, and an ambeta/alpha1-AT chimeric peptide, composed of the amino-terminal domain of ambeta and the carboxyl-terminal domain of alpha1-AT, compete for binding of I-peptide 105Y and I-Yambeta-(25-35) to HepG2 to a similar extent (Fig. 5). Seventh, receptor-mediated endocytosis of I-Yambeta-(25-35) is blocked by peptide 105Y (Fig. 6). Eighth, peptide 105Y completely abrogates the neutrophil chemotactic effect of amyloid-beta-(25-35) by homologous desensitization(3) , providing additional pharmacological evidence that peptide 105Y and amyloid-beta peptide bind to the same receptor in neutrophils. It will be necessary, however, to isolate cDNA clones for SEC-R and express SEC-R cDNA in a heterologous cell to provide definitive evidence that peptide 105Y and soluble amyloid-beta-peptide both bind to it.

The results of this study may also have important implications for the pathogenesis of Alzheimer's disease(17, 18, 19, 20) . Amyloid-beta peptide is known to be a major constituent of the amyloid plaques found in the brains of individuals with Alzheimer's disease. There is a growing body of evidence that the amyloid-beta peptide is generated as a free soluble peptide under physiologic circumstances as a result of an alternative post-translational processing pathway(12, 13, 14, 15, 16) . In Alzheimer's disease there is greater use of this alternative processing pathway and more amyloid-beta peptide generated(21, 22, 23) . Presumably, this amyloid-beta peptide accumulates in the brain and over time undergoes aggregation. A structure termed the ``mature plaque'' is found in brain during aging. Ultimately there is ingrowth of neurites, neurofibrillary degeneration, and ingrowth/activation of microglia into the plaque to form the ``senile plaque'' associated with the development of dementia(17, 18, 19, 20) . The results of the current experiments indicate that SEC-R can mediate clearance and intracellular catabolism of soluble amyloid-beta peptide in cells that are derived from the central nervous system. Perhaps, it functions to protect the CNS from excessive extracellular amyloid-beta peptide accumulation but gets overwhelmed over time in individuals predisposed to Alzheimer's disease.

The results of this study are only applicable to amyloid-beta peptide that is completely soluble. In a previous study using radioiodinated amyloid-beta peptides there was no evidence for receptor-mediated endocytosis and degradation in human skin fibroblasts(24) . These results could be due to the substantial degree of variability in expression of SEC-R in human skin fibroblast cell lines. Some skin fibroblasts do not express SEC-R. Even in human skin fibroblast cell lines that express SEC-R, there is a much lower number of SEC-R molecules/cell than in HepG2 cells or PC12 cells. (^2)It will now be informative to compare the relative binding of insoluble amyloid-beta peptides with that of soluble amyloid-beta peptides, as studied here, in cell lines such as PC12 and HepG2, which express a substantial number of SEC-R molecules per cell. A number of studies over the last several years have shown that amyloid-beta peptide-(25-35), and peptides that contain the region corresponding to amyloid-beta-(25-35), when prepared in an insoluble, aggregated form, are toxic to neurons(7, 25, 26, 27, 28, 29) . The most recent of these studies suggest that the toxic interaction of insoluble amyloid-beta peptide-(25-35) with cells is not sequence-specific but is correlated with formation of insoluble fibrils (30) or correlated with the sequence specificity required for formation of insoluble fibrils(31) .


FOOTNOTES

*
The studies were supported in part by U.S. Public Health Service grants HL-37784 and AG11577, by the Monsanto-Washington University Biomedical funding program, and by a Burroughs Wellcome Trust Experimental Therapeutics Scholar Award (to D. H. P.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore by hereby marked ``advertisement'' in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

§
To whom correspondence should be addressed: Dept. of Pediatrics, Washington University School of Medicine, St. Louis Children's Hospital, One Children's Place, St. Louis, MO 63110. Tel.: 314-454-6033; Fax: 314-424-2412.

(^1)
The abbreviations used are: SEC-R, SEC receptor; SEC, serpin-enzyme complex; ambeta, amyloid-beta; Yambeta, Y ambeta; PBS, phosphate-buffered saline; alpha1-AT, alpha1-antitrypsin.

(^2)
D. H. Perlmutter, unpublished observations.


ACKNOWLEDGEMENTS

We are indebted to Joyce L. Williams for preparing the manuscript.


REFERENCES

  1. Perlmutter, D. H. (1994) Pediatr. Res. 36, 271-277 [Medline] [Order article via Infotrieve]
  2. Perlmutter, D. H., Glover, G. I., Rivetna, M., Schasteen, C. S., and Fallon, R. J. (1990) Proc. Natl. Acad. Sci. U. S. A. 87, 3753-3757 [Abstract]
  3. Joslin, G., Wittwer, A., Adams, S., Tollefsen, D. M., August, A., and Perlmutter, D. H. (1993) J. Biol. Chem. 268, 1886-1893 [Abstract/Free Full Text]
  4. Perlmutter, D. H., Joslin, G., Nelson, P., Schasteen, C., Adams, S. P., and Fallon, R. J. (1990) J. Biol. Chem. 265, 16713-16716 [Abstract/Free Full Text]
  5. Joslin, G., Griffin, G. L., August, A. M., Adams, S., Fallon, R. J., Senior, R. M., and Perlmutter, D. H. (1992) J. Clin. Invest. 90, 1150-1154 [Medline] [Order article via Infotrieve]
  6. Joslin, G., Fallon, R. J., Bullock, J., Adams, S. P., and Perlmutter, D. H. (1991) J. Biol. Chem. 266, 11281-11288
  7. Yanker, B. A., Duffy, L. K., and Kirschner, D. A. (1990) Science 25, 279-282
  8. Joslin, G., Krause, J. E., Hershey, A. D., Adams, S. P., Fallon, R. J., and Perlmutter, D. H. (1991) J. Biol. Chem. 266, 21897-21902 [Abstract/Free Full Text]
  9. Choi, D. W., Maulucci-Gedde, M., and Kriegstein, A. R. (1987) J. Neurosci. 7, 357-368 [Abstract]
  10. Owensby, D. A., Sobel, B. E., and Schwartz, A. L. (1988) J. Biol. Chem. 263, 10587-10594 [Abstract/Free Full Text]
  11. Schwartz, A. L., Fridovich, S. E., and Lodish, H. F. (1982) J. Biol. Chem. 257, 4230-4237 [Free Full Text]
  12. Estus, S., Golde, T. E., Kinishita, T., Blades, D., Lowery, D., Eisen, M., Ustak, M., Qu, K., Tabira, T., Greenberg, B. D., and Younkin, S. G. (1992) Science 255, 726-728 [Medline] [Order article via Infotrieve]
  13. Golde, T. E., Estus, S., Younkin, L. H., Selkoe, D. J., and Younkin, S. G. (1992) Science 255, 728-730 [Medline] [Order article via Infotrieve]
  14. Haass, C., Schlossmacher, M. G., Hung, A. Y., Vigo-Pelfrey, C., Mellon, A., Ostaszewski, B. L., Lieberburg, I., Koo, E. H., Schenk, D., Teplow, D. B., and Selkoe, D. J. (1992) Nature 359, 322-325 [CrossRef][Medline] [Order article via Infotrieve]
  15. Seubert, P., Vigo-Pelfrey, C., Esch, F., Lee, M., Dovey, H., Davis, D., Sinha, S., Schlossmacher, M., Whaley, J., Swindlehurst, C., McCormack, R., Wolfert, R., Selkoe, D. J., Lieberburg, I., and Schenk, D. (1992) Nature 359, 325-327 [CrossRef][Medline] [Order article via Infotrieve]
  16. Seubert, P., Oltersdorf, T., Lee, M. G., Barbour, R., Blomquist, C., David, D. L., Bryant, K., Fritz, L. C., Douglas Galasko, D., Thal, L. J, Lieberburg, I., and Schenk, D. B. (1993) Nature 361, 260-263 [CrossRef][Medline] [Order article via Infotrieve]
  17. Kosik, K. S. (1994) J. Cell Biol. 127, 1501-1504 [Medline] [Order article via Infotrieve]
  18. Price, D. L., Rorchell, D. R., and Sisodia, S. S. (1993) Proc. Natl. Acad. Sci. U. S. A. 90, 6381-6384 [Abstract]
  19. Yankner, B. A., and Mesulam, M-M. (1991) N. Engl. J. Med. 325, 1849-1857 [Medline] [Order article via Infotrieve]
  20. Selkoe, D. J. (1994) Annu. Rev. Neurosci. 17, 489-517 [CrossRef][Medline] [Order article via Infotrieve]
  21. Cai, X-D., Golde, T. E., and Younkin, S. G. (1993) Science 259, 514-516 [Medline] [Order article via Infotrieve]
  22. Suzuki, N., Cheung, T. T., Cai, X-D., Odaka, A., Otvos, L., Jr., Eckman, C., Golde, T. E., and Younkin, S. G. (1994) Science 264, 1336-1340 [Medline] [Order article via Infotrieve]
  23. Haass, C., Hung, A. Y., Selkoe, D. J., and Teplow, D. B. (1994) J. Biol. Chem. 269, 17741-17748 [Abstract/Free Full Text]
  24. Knauer, M. F., Soreghan, B., Burdick, D., Kosmoski, J., and Glabe, C. G. (1992) Proc. Natl. Acad. Sci. U. S. A. 99, 7437-7441
  25. Pike, C. J., Burdick, D., Walencewicz, A. J., Glabe, C. G., and Cotman, C. W. (1992) J. Neurosci. 13, 1676-1687 [Abstract]
  26. Behl, C., Davis, J. B., Lesley, R., and Schubert, D. (1994) Cell 77, 817-827 [Medline] [Order article via Infotrieve]
  27. Lorenzo, A., and Yankner, B. A. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 12243-12247 [Abstract/Free Full Text]
  28. Mattson, M. P., Tomaselli, K. J., and Rydel, R. E. (1993) Brain Res. 621, 35-49 [CrossRef][Medline] [Order article via Infotrieve]
  29. Forloni, G., Chiesa, R., Smiroldo, S., Verga, L., Salmona, M., Tagliavini, F., and Angeretti, N. (1993) Neuroreport 4, 523-526 [Medline] [Order article via Infotrieve]
  30. Lorenzo, A., Razzaboni, B., Weir, G. C., and Yankner, B. A. (1994) Nature 368, 756-760 [CrossRef][Medline] [Order article via Infotrieve]
  31. Pike, C. J., Walencewicz-Wasserman, A. J., Kosmoski, J., Cribbs, D. H., Glabe, C. G., and Cotman, C. W. (1995) J. Neurochem. 64, 253-265 [Medline] [Order article via Infotrieve]

©1995 by The American Society for Biochemistry and Molecular Biology, Inc.